Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SR4G
|
|||
| Former ID |
DIB005924
|
|||
| Drug Name |
ONT-093
|
|||
| Synonyms |
MDR inhibitors, Ontogen; OC-144-093
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Discontinued in Phase 1 | [1] | |
| Company |
Ontogen Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H38N4O
|
|||
| Canonical SMILES |
CCOCC=CC1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=C(C=C3)NC(C)C)C4=CC=C(C=C4)NC(C)C
|
|||
| InChI |
1S/C32H38N4O/c1-6-37-21-7-8-24-9-11-27(12-10-24)32-35-30(25-13-17-28(18-14-25)33-22(2)3)31(36-32)26-15-19-29(20-16-26)34-23(4)5/h7-20,22-23,33-34H,6,21H2,1-5H3,(H,35,36)/b8-7+
|
|||
| InChIKey |
RSJCLODJSVZNQA-BQYQJAHWSA-N
|
|||
| CAS Number |
CAS 216227-54-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Multidrug resistance protein 1 (ABCB1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | ABC transporters | |||
| Bile secretion | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Abacavir transport and metabolism | ||||
| Multi Drug Resistance Protein 1 (Glycoprotein 1) Regulation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Allograft Rejection | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Codeine and Morphine Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011621) | |||
| REF 2 | A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.